|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0760 USD | +8.57% |
|
+5.56% | +23.98% |
| 05-20 | Radnostix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 04-03 | Radnostix Inc Voluntary Recalls Gelatin Capsule Pack for Use with the Sodium Iodide I-131 Kit | CI |
| Market Cap | 40.21M 35.33M 32.55M 30.47M 57.09M 3.81B 58.06M 391M 151M 1.87B 151M 148M 6.5B | P/E 2024 |
2,150x | P/E 2025 | -35.5x |
|---|---|---|---|---|---|
| Enterprise Value | 47.42M 41.66M 38.39M 35.93M 67.33M 4.49B 68.46M 461M 178M 2.2B 178M 174M 7.66B | EV / Sales 2024 |
1.76x | EV / Sales 2025 | 3.03x |
| Free-Float |
26.53% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +8.57% | ||
| 1 week | +5.56% | ||
| Current month | -9.31% | ||
| 1 month | +3.97% | ||
| 3 months | -11.42% | ||
| 6 months | +27.73% | ||
| Current year | +23.98% |
| 1 week | 0.07 |  | 0.08 |
| 1 month | 0.07 | | 0.08 |
| Current year | 0.05 | | 0.1 |
| 1 year | 0.05 | | 0.11 |
| 3 years | 0.02 | | 0.11 |
| 5 years | 0.02 | | 0.15 |
| 10 years | 0 | | 0.34 |
| Manager | Title | Age | Since |
|---|---|---|---|
Shahe Bagerdjian
CEO | Chief Executive Officer | 41 | 2023-08-31 |
W. Cox
DFI | Director of Finance/CFO | 42 | 2019-09-29 |
John Miller
LAW | General Counsel | 61 | 2000-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Steve Laflin
BRD | Director/Board Member | 69 | 2001-05-31 |
| Chairman | 58 | 2017-06-30 | |
Robert Atcher
BRD | Director/Board Member | 74 | 2017-08-01 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 25-10-09 | Free | Chairman | 500,000 | 0.0955% | ||
| 25-10-09 | Free | Director | 500,000 | 0.0955% | ||
| 25-10-09 | Free | Director | 250,000 | 0.0478% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +8.57% | +5.56% | +27.73% | +2.70% | 37.04M | |
| -0.93% | +15.73% | -21.91% | -42.71% | 2.85B | |
| -2.21% | +9.38% | -8.53% | -84.87% | 1.86B | |
| -4.68% | -10.35% | -13.02% | -3.74% | 302M | |
| -5.05% | -12.86% | -45.73% | - | 55.63M | |
| Average | -0.86% | +0.75% | -12.29% | -32.15% | 1.02B | |
| Weighted average by Cap. | -1.59% | +11.59% | -16.40% | -55.60% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 13.9M 12.21M 11.25M 10.53M 19.73M 1.32B 20.07M 135M 52.3M 646M 52.18M 51.06M 2.25B | 13.07M 11.48M 10.58M 9.9M 18.56M 1.24B 18.87M 127M 49.18M 607M 49.07M 48.01M 2.11B |
| Net income | 8.57K 7.53K 6.94K 6.5K 12.17K 812K 12.38K 83.34K 32.26K 399K 32.19K 31.49K 1.39M | -908K -798K -735K -688K -1.29M -86.01M -1.31M -8.83M -3.42M -42.2M -3.41M -3.34M -147M |
| Net Debt | 6.42M 5.64M 5.19M 4.86M 9.11M 608M 9.26M 62.37M 24.14M 298M 24.09M 23.57M 1.04B | 7.21M 6.33M 5.83M 5.46M 10.23M 683M 10.4M 70.04M 27.11M 335M 27.05M 26.47M 1.16B |
Employees
45
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-23 | US$0.0760 | +8.57% | 500 |
| 26-06-22 | US$0.0700 | -3.71% | 1,830 |
| 26-06-18 | US$0.0727 | +3.86% | 1,488 |
| 26-06-17 | US$0.0700 | -2.75% | 76,304 |
| 26-06-16 | US$0.0720 | +2.83% | 7,692 |
- Stock Market
- Stocks
- INIS Stock
Select your edition
All financial news and data tailored to specific country editions
